NQ HCIF GP, Ltd.

Q4 2014 13F Holdings Report, Stock Holdings

Signature - Title
John L. Bradley, Jr. - Director
Location
Raleigh, NC
Holdings as of
31 Dec 2014
Value $
$52,457,000
Num holdings
1
Filing time
17 Feb 2015, 08:30:56 UTC
Form type
13F-HR
Description
All US holdings of this investor are reported in this report. Top holdings included RVNC.
Next filing
Q1 2015 - 28 Apr 2015
Sym Weight Trade Impact Company Class Share Change Activity Value Change $ Value $ * Price $ Shares Principal
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
John L. Bradley, Jr. Director Raleigh, North Carolina 17 Feb 2015

The securities listed in the table below are held by NovaQuest Pharma Opportunities Fund III, L.P. ("NovaQuest"). NQ HCIF General Partner, L.P., the general partner of NovaQuest ("NovaQuest GP"), may be deemed to exercise investment discretion with respect to the securities directly owned by NovaQuest, and NQ HCIF GP, Ltd., the general partner of NovaQuest GP ("NovaQuest GP Ltd."), may be deemed to direct NovaQuest GP as to such investment discretion. The filing of this report or any related report shall not be deemed an admission, for purposes of Section 13(f), 13(d), 13(g) or 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder, or for any other purpose, that NovaQuest GP, NovaQuest GP Ltd. or any other person exercises investment discretion with respect to the securities listed herein or is a member of, or is otherwise affiliated with, such a group with respect to such securities. Reference is made, where relevant, to reports filed under Sections 13(d), 13(g) and 16(a) of the Exchange Act for additional information with respect to such beneficial ownership and/or pecuniary interest of NovaQuest GP and NovaQuest GP Ltd. The filing of this report or any related report shall not be deemed an admission, for purposes of Section 13(f), 13(d), 13(g) or 16(a) of the Exchange Act and the rules thereunder, or for any other purpose, that NovaQuest GP and NovaQuest GP Ltd. or any other person is the beneficial owner of any securities.

Other Included Managers (2):

Num Name Location File Number
2 NovaQuest Pharma Opportunities Fund III, L.P. Raleigh, NC
3 NQ HCIF General Partner, L.P. Raleigh, NC